Drugs / IAMA-6
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06300398 | Jan → Oct 2024 | neurodevelopmental disorder | Iama Therapeutics S.r.l. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-12-20 | Iama Therapeutics S.r.l. | Regulatory IAMA Therapeutics Announces Approval of Clinical Trial Application (CTA) by the Italian Medicines Agency (AIFA) to Initiate a Phase 1 Study of IAMA-6 for the Treatment of Autism and Epilepsy iamatherapeutics.com ↗
IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain disorders, today announced that the Italian Medicines Agency (AIFA) has accepted the Clinical Trial Application (CTA) to initiate a Phase 1 first-in-human (FIH), randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of IAMA’s lead program IAMA-6, an orally administered small molecule therapeutic targeting NKCC1 for the treatment of autism and epilepsy. |
| 2023-12-01 | Iama Therapeutics S.r.l. | Results IAMA Therapeutics to Present New Preclinical Data at Upcoming American Epilepsy Society 2023 Annual Meeting iamatherapeutics.com ↗
Importantly, IAMA-6 restores correct inhibition directly in brain preparations from patients with MTLE. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-01-23 | Iama Therapeutics S.r.l. | IAMA Therapeutics Announces First Subject Dosed in Phase 1 Study of IAMA-6 for the Treatment of Autism and Epilepsy iamatherapeutics.com ↗ |
| 2023-12-20 | Iama Therapeutics S.r.l. | IAMA Therapeutics Announces Approval of Clinical Trial Application (CTA) by the Italian Medicines Agency (AIFA) to Initiate a Phase 1 Study of IAMA-6 for the Treatment of Autism and Epilepsy iamatherapeutics.com ↗ |
| 2023-12-01 | Iama Therapeutics S.r.l. | IAMA Therapeutics to Present New Preclinical Data at Upcoming American Epilepsy Society 2023 Annual Meeting iamatherapeutics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IAMA-6 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06300398 ↗ |
| Route | Oral | “IAMA-6 administered orally” NCT06300398 ↗ |